Use of Lesion Response Rate in Actinic Keratosis Trials

Use of Lesion Response Rate in Actinic Keratosis Trials

Complete patient clearance is often required by regulatory agencies for the approval of treatments for actinic keratosis (AK). However, an increasing number of clinicians have challenged the use of this measure in clinical practice and its interpretation. It has been argued that complete patient clearance often underestimates the clinical benefit of a drug and is influenced by a number of key c...

Sunlight (actinic) keratosis: an update.

L. FELLER, R.A.G. KHAMMISSA, N.H. WooD, Y. JADWAT, R. MEYERoV, J. LEMMER Department of Periodontology and oral Medicine, School of Dentistry, Faculty of Health Sciences, University of Limpopo, Medunsa Campus, South Africa; * School of Dentistry, Faculty of Health Sciences, University of Limpopo, Medunsa Campus, South Africa Professor Emeritus: University of Witwatersrand, Johannesburg, Universi...

Sebaceous carcinoma with actinic keratosis.

Optimal treatment of actinic keratosis

License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be f...

Actinic Keratosis: Rationale and Management

Actinic keratoses (AKs) are common skin lesions heralding an increased risk of developing squamous cell carcinoma (SCC) and other skin malignancies, arising principally due to excessive ultraviolet (UV) exposure. They are predominantly found in fair-skinned individuals, and increasingly, are a problem of the immunosuppressed. AKs may regress spontaneously, remain stable or transform to invasive...